Skip to main content
Top
Published in: BMC Cancer 1/2013

Open Access 01-12-2013 | Research article

Preoperative serum C- reactive protein: a prognostic marker in patients with upper urinary tract urothelial carcinoma

Authors: Barbara Stein, Andres Jan Schrader, Gerd Wegener, Christoph Seidel, Markus A Kuczyk, Sandra Steffens

Published in: BMC Cancer | Issue 1/2013

Login to get access

Abstract

Background

To analyse the prognostic significance of preoperative C-reactive protein (CRP) serum level in patients with upper urinary tract urothelial carcinoma (UUT-UC).

Methods

We evaluated 158 UUT-UC patients who had undergone surgery in the University Hospital of Hannover (MHH). 143 (89.4%) suffered from cancer in the renal pelvis, 13 (8.1%) patients presented with tumour located in the ureter. A preoperative CRP value was available for 115 patients. The mean (median) follow-up for these patients was 28.3 (15.1) months.

Results

The median (mean) CRP value of all evaluable patients was 10.0 (40.7) mg/l. The CRP-level, stratified into two subgroups (CRP ≤5 vs. >5 mg/l), correlated significantly with muscle invasive tumour stage (36.4 vs. 78.9%; p<0.001), the risk of presenting nodal disease (4.5 vs. 26.8%; p=0.002) and distant metastasis (2.3 vs. 16.9%; p<0.016). The Kaplan-Meier 5-year cancer specific survival (CSS) rates were 54.2 and 26.4% for patients with preoperative CRP levels ≤ and >5 mg/l, respectively (p<0.006). Next to age and the presence of metastasis, multivariate analysis also identified CRP as a continuous variable as an independent prognosticator for CSS.

Conclusions

A high preoperative serum CRP level is associated with locally advanced and metastatic disease in patients with UUT-UC. Its routine use could allow better risk stratification and risk-adjusted follow-up of UUT-UC patients.
Appendix
Available only for authorised users
Literature
1.
go back to reference Munoz JJ, Ellison LM: Upper tract urothelial neoplasms: incidence and survival during the last 2 decades. J Urol. 2000, 164 (5): 1523-1525. 10.1016/S0022-5347(05)67019-X.CrossRefPubMed Munoz JJ, Ellison LM: Upper tract urothelial neoplasms: incidence and survival during the last 2 decades. J Urol. 2000, 164 (5): 1523-1525. 10.1016/S0022-5347(05)67019-X.CrossRefPubMed
2.
go back to reference Corrado F, Mannini D, Ferri C, Corrado G, Bertoni F, Bacchini P, Lieber MM, Song JM: The prognostic significance of DNA ploidy pattern in transitional cell cancer of the renal pelvis and ureter: continuing follow-up. Eur Urol. 1992, 21 (Suppl 1): 48-50.PubMed Corrado F, Mannini D, Ferri C, Corrado G, Bertoni F, Bacchini P, Lieber MM, Song JM: The prognostic significance of DNA ploidy pattern in transitional cell cancer of the renal pelvis and ureter: continuing follow-up. Eur Urol. 1992, 21 (Suppl 1): 48-50.PubMed
3.
go back to reference Hall MC, Womack S, Sagalowsky AI, Carmody T, Erickstad MD, Roehrborn CG: Prognostic factors, recurrence, and survival in transitional cell carcinoma of the upper urinary tract: a 30-year experience in 252 patients. Urology. 1998, 52 (4): 594-601. 10.1016/S0090-4295(98)00295-7.CrossRefPubMed Hall MC, Womack S, Sagalowsky AI, Carmody T, Erickstad MD, Roehrborn CG: Prognostic factors, recurrence, and survival in transitional cell carcinoma of the upper urinary tract: a 30-year experience in 252 patients. Urology. 1998, 52 (4): 594-601. 10.1016/S0090-4295(98)00295-7.CrossRefPubMed
4.
go back to reference Kikuchi E, Horiguchi Y, Nakashima J, Hatakeyama N, Matsumoto M, Nishiyama T, Murai M: Lymphovascular invasion independently predicts increased disease specific survival in patients with transitional cell carcinoma of the upper urinary tract. J Urol. 2005, 174 (6): 2120-2123. 10.1097/01.ju.0000181801.22474.8b. discussion 2124CrossRefPubMed Kikuchi E, Horiguchi Y, Nakashima J, Hatakeyama N, Matsumoto M, Nishiyama T, Murai M: Lymphovascular invasion independently predicts increased disease specific survival in patients with transitional cell carcinoma of the upper urinary tract. J Urol. 2005, 174 (6): 2120-2123. 10.1097/01.ju.0000181801.22474.8b. discussion 2124CrossRefPubMed
5.
go back to reference Ozsahin M, Zouhair A, Villa S, Storme G, Chauvet B, Taussky D, Gouders D, Ries G, Bontemps P, Coucke PA: Prognostic factors in urothelial renal pelvis and ureter tumours: a multicentre Rare Cancer Network study. Eur J Cancer. 1999, 35 (5): 738-743. 10.1016/S0959-8049(99)00012-X.CrossRefPubMed Ozsahin M, Zouhair A, Villa S, Storme G, Chauvet B, Taussky D, Gouders D, Ries G, Bontemps P, Coucke PA: Prognostic factors in urothelial renal pelvis and ureter tumours: a multicentre Rare Cancer Network study. Eur J Cancer. 1999, 35 (5): 738-743. 10.1016/S0959-8049(99)00012-X.CrossRefPubMed
6.
go back to reference Park S, Hong B, Kim CS, Ahn H: The impact of tumor location on prognosis of transitional cell carcinoma of the upper urinary tract. J Urol. 2004, 171 (2 Pt 1): 621-625.CrossRefPubMed Park S, Hong B, Kim CS, Ahn H: The impact of tumor location on prognosis of transitional cell carcinoma of the upper urinary tract. J Urol. 2004, 171 (2 Pt 1): 621-625.CrossRefPubMed
7.
go back to reference Allin KH, Bojesen SE, Nordestgaard BG: Baseline C-reactive protein is associated with incident cancer and survival in patients with cancer. J Clin Oncol. 2009, 27 (13): 2217-2224. 10.1200/JCO.2008.19.8440.CrossRefPubMed Allin KH, Bojesen SE, Nordestgaard BG: Baseline C-reactive protein is associated with incident cancer and survival in patients with cancer. J Clin Oncol. 2009, 27 (13): 2217-2224. 10.1200/JCO.2008.19.8440.CrossRefPubMed
8.
go back to reference McArdle PA, Mir K, Almushatat AS, Wallace AM, Underwood MA, McMillan DC: Systemic inflammatory response, prostate-specific antigen and survival in patients with metastatic prostate cancer. Urol Int. 2006, 77 (2): 127-129. 10.1159/000093905.CrossRefPubMed McArdle PA, Mir K, Almushatat AS, Wallace AM, Underwood MA, McMillan DC: Systemic inflammatory response, prostate-specific antigen and survival in patients with metastatic prostate cancer. Urol Int. 2006, 77 (2): 127-129. 10.1159/000093905.CrossRefPubMed
9.
go back to reference Iimura Y, Saito K, Fujii Y, Kumagai J, Kawakami S, Komai Y, Yonese J, Fukui I, Kihara K: Development and external validation of a new outcome prediction model for patients with clear cell renal cell carcinoma treated with nephrectomy based on preoperative serum C-reactive protein and TNM classification: the TNM-C score. J Urol. 2009, 181 (3): 1004-1012. 10.1016/j.juro.2008.10.156. discussion 1012CrossRefPubMed Iimura Y, Saito K, Fujii Y, Kumagai J, Kawakami S, Komai Y, Yonese J, Fukui I, Kihara K: Development and external validation of a new outcome prediction model for patients with clear cell renal cell carcinoma treated with nephrectomy based on preoperative serum C-reactive protein and TNM classification: the TNM-C score. J Urol. 2009, 181 (3): 1004-1012. 10.1016/j.juro.2008.10.156. discussion 1012CrossRefPubMed
10.
go back to reference Kawata N, Nagane Y, Yamaguchi K, Ichinose T, Hirakata H, Takahashi S: How do symptoms have an impact on the prognosis of renal cell carcinoma?. Int J Urol. 2008, 15 (4): 299-303. 10.1111/j.1442-2042.2008.01990.x.CrossRefPubMed Kawata N, Nagane Y, Yamaguchi K, Ichinose T, Hirakata H, Takahashi S: How do symptoms have an impact on the prognosis of renal cell carcinoma?. Int J Urol. 2008, 15 (4): 299-303. 10.1111/j.1442-2042.2008.01990.x.CrossRefPubMed
11.
go back to reference Komai Y, Saito K, Sakai K, Morimoto S: Increased preoperative serum C-reactive protein level predicts a poor prognosis in patients with localized renal cell carcinoma. BJU Int. 2007, 99 (1): 77-80. 10.1111/j.1464-410X.2006.06497.x.CrossRefPubMed Komai Y, Saito K, Sakai K, Morimoto S: Increased preoperative serum C-reactive protein level predicts a poor prognosis in patients with localized renal cell carcinoma. BJU Int. 2007, 99 (1): 77-80. 10.1111/j.1464-410X.2006.06497.x.CrossRefPubMed
12.
go back to reference Ito K, Asano T, Yoshii H, Satoh A, Sumitomo M, Hayakawa M: Impact of thrombocytosis and C-reactive protein elevation on the prognosis for patients with renal cell carcinoma. Int J Urol. 2006, 13 (11): 1365-1370. 10.1111/j.1442-2042.2006.01563.x.CrossRefPubMed Ito K, Asano T, Yoshii H, Satoh A, Sumitomo M, Hayakawa M: Impact of thrombocytosis and C-reactive protein elevation on the prognosis for patients with renal cell carcinoma. Int J Urol. 2006, 13 (11): 1365-1370. 10.1111/j.1442-2042.2006.01563.x.CrossRefPubMed
13.
go back to reference Jabs WJ, Busse M, Kruger S, Jocham D, Steinhoff J, Doehn C: Expression of C-reactive protein by renal cell carcinomas and unaffected surrounding renal tissue. Kidney Int. 2005, 68 (5): 2103-2110. 10.1111/j.1523-1755.2005.00666.x.CrossRefPubMed Jabs WJ, Busse M, Kruger S, Jocham D, Steinhoff J, Doehn C: Expression of C-reactive protein by renal cell carcinomas and unaffected surrounding renal tissue. Kidney Int. 2005, 68 (5): 2103-2110. 10.1111/j.1523-1755.2005.00666.x.CrossRefPubMed
14.
go back to reference Karakiewicz PI, Hutterer GC, Trinh QD, Jeldres C, Perrotte P, Gallina A, Tostain J, Patard JJ: C-reactive protein is an informative predictor of renal cell carcinoma-specific mortality: a European study of 313 patients. Cancer. 2007, 110 (6): 1241-1247. 10.1002/cncr.22896.CrossRefPubMed Karakiewicz PI, Hutterer GC, Trinh QD, Jeldres C, Perrotte P, Gallina A, Tostain J, Patard JJ: C-reactive protein is an informative predictor of renal cell carcinoma-specific mortality: a European study of 313 patients. Cancer. 2007, 110 (6): 1241-1247. 10.1002/cncr.22896.CrossRefPubMed
15.
go back to reference Lamb GW, McArdle PA, Ramsey S, McNichol AM, Edwards J, Aitchison M, McMillan DC: The relationship between the local and systemic inflammatory responses and survival in patients undergoing resection for localized renal cancer. BJU Int. 2008, 102 (6): 756-761. 10.1111/j.1464-410X.2008.07666.x.CrossRefPubMed Lamb GW, McArdle PA, Ramsey S, McNichol AM, Edwards J, Aitchison M, McMillan DC: The relationship between the local and systemic inflammatory responses and survival in patients undergoing resection for localized renal cancer. BJU Int. 2008, 102 (6): 756-761. 10.1111/j.1464-410X.2008.07666.x.CrossRefPubMed
16.
go back to reference Ramsey S, Lamb GW, Aitchison M, McMillan DC: Prospective study of the relationship between the systemic inflammatory response, prognostic scoring systems and relapse-free and cancer-specific survival in patients undergoing potentially curative resection for renal cancer. BJU Int. 2008, 101 (8): 959-963. 10.1111/j.1464-410X.2007.07363.x.CrossRefPubMed Ramsey S, Lamb GW, Aitchison M, McMillan DC: Prospective study of the relationship between the systemic inflammatory response, prognostic scoring systems and relapse-free and cancer-specific survival in patients undergoing potentially curative resection for renal cancer. BJU Int. 2008, 101 (8): 959-963. 10.1111/j.1464-410X.2007.07363.x.CrossRefPubMed
17.
go back to reference Steffens S, Kohler A, Rudolph R, Eggers H, Seidel C, Janssen M, Wegener G, Schrader M, Kuczyk MA, Schrader AJ: Validation of CRP as prognostic marker for renal cell carcinoma in a large series of patients. BMC Cancer. 2012, 12 (1): 399-10.1186/1471-2407-12-399.CrossRefPubMedPubMedCentral Steffens S, Kohler A, Rudolph R, Eggers H, Seidel C, Janssen M, Wegener G, Schrader M, Kuczyk MA, Schrader AJ: Validation of CRP as prognostic marker for renal cell carcinoma in a large series of patients. BMC Cancer. 2012, 12 (1): 399-10.1186/1471-2407-12-399.CrossRefPubMedPubMedCentral
18.
go back to reference Trichopoulos D, Psaltopoulou T, Orfanos P, Trichopoulou A, Boffetta P: Plasma C-reactive protein and risk of cancer: a prospective study from Greece. Cancer Epidemiol Biomarkers Prev. 2006, 15 (2): 381-384. 10.1158/1055-9965.EPI-05-0626.CrossRefPubMed Trichopoulos D, Psaltopoulou T, Orfanos P, Trichopoulou A, Boffetta P: Plasma C-reactive protein and risk of cancer: a prospective study from Greece. Cancer Epidemiol Biomarkers Prev. 2006, 15 (2): 381-384. 10.1158/1055-9965.EPI-05-0626.CrossRefPubMed
19.
go back to reference Yoshida S, Saito K, Koga F, Yokoyama M, Kageyama Y, Masuda H, Kobayashi T, Kawakami S, Kihara K: C-reactive protein level predicts prognosis in patients with muscle-invasive bladder cancer treated with chemoradiotherapy. BJU Int. 2008, 101 (8): 978-981. 10.1111/j.1464-410X.2007.07408.x.CrossRefPubMed Yoshida S, Saito K, Koga F, Yokoyama M, Kageyama Y, Masuda H, Kobayashi T, Kawakami S, Kihara K: C-reactive protein level predicts prognosis in patients with muscle-invasive bladder cancer treated with chemoradiotherapy. BJU Int. 2008, 101 (8): 978-981. 10.1111/j.1464-410X.2007.07408.x.CrossRefPubMed
20.
go back to reference Saito K, Kawakami S, Ohtsuka Y, Fujii Y, Masuda H, Kumagai J, Kobayashi T, Kageyama Y, Kihara K: The impact of preoperative serum C-reactive protein on the prognosis of patients with upper urinary tract urothelial carcinoma treated surgically. BJU Int. 2007, 100 (2): 269-273. 10.1111/j.1464-410X.2007.06934.x.CrossRefPubMed Saito K, Kawakami S, Ohtsuka Y, Fujii Y, Masuda H, Kumagai J, Kobayashi T, Kageyama Y, Kihara K: The impact of preoperative serum C-reactive protein on the prognosis of patients with upper urinary tract urothelial carcinoma treated surgically. BJU Int. 2007, 100 (2): 269-273. 10.1111/j.1464-410X.2007.06934.x.CrossRefPubMed
21.
go back to reference Nakanishi H, Araki N, Kudawara I, Kuratsu S, Matsumine A, Mano M, Naka N, Myoui A, Ueda T, Yoshikawa H: Clinical implications of serum C-reactive protein levels in malignant fibrous histiocytoma. Int J Cancer. 2002, 99 (2): 167-170. 10.1002/ijc.10343.CrossRefPubMed Nakanishi H, Araki N, Kudawara I, Kuratsu S, Matsumine A, Mano M, Naka N, Myoui A, Ueda T, Yoshikawa H: Clinical implications of serum C-reactive protein levels in malignant fibrous histiocytoma. Int J Cancer. 2002, 99 (2): 167-170. 10.1002/ijc.10343.CrossRefPubMed
22.
go back to reference Canna K, McArdle PA, McMillan DC, McNicol AM, Smith GW, McKee RF, McArdle CS: The relationship between tumour T-lymphocyte infiltration, the systemic inflammatory response and survival in patients undergoing curative resection for colorectal cancer. Br J Cancer. 2005, 92 (4): 651-654. 10.1038/sj.bjc.6602419.CrossRefPubMedPubMedCentral Canna K, McArdle PA, McMillan DC, McNicol AM, Smith GW, McKee RF, McArdle CS: The relationship between tumour T-lymphocyte infiltration, the systemic inflammatory response and survival in patients undergoing curative resection for colorectal cancer. Br J Cancer. 2005, 92 (4): 651-654. 10.1038/sj.bjc.6602419.CrossRefPubMedPubMedCentral
23.
go back to reference Du Clos TW, Mold C: C-reactive protein: an activator of innate immunity and a modulator of adaptive immunity. Immunol Res. 2004, 30 (3): 261-277. 10.1385/IR:30:3:261.CrossRefPubMed Du Clos TW, Mold C: C-reactive protein: an activator of innate immunity and a modulator of adaptive immunity. Immunol Res. 2004, 30 (3): 261-277. 10.1385/IR:30:3:261.CrossRefPubMed
24.
go back to reference Maccio A, Lai P, Santona MC, Pagliara L, Melis GB, Mantovani G: High serum levels of soluble IL-2 receptor, cytokines, and C reactive protein correlate with impairment of T cell response in patients with advanced epithelial ovarian cancer. Gynecol Oncol. 1998, 69 (3): 248-252. 10.1006/gyno.1998.4974.CrossRefPubMed Maccio A, Lai P, Santona MC, Pagliara L, Melis GB, Mantovani G: High serum levels of soluble IL-2 receptor, cytokines, and C reactive protein correlate with impairment of T cell response in patients with advanced epithelial ovarian cancer. Gynecol Oncol. 1998, 69 (3): 248-252. 10.1006/gyno.1998.4974.CrossRefPubMed
25.
go back to reference Matsumoto K, Kinoshita T, Ishida T, Itoh H, Miki C, Suzuki H: Serum levels of NCC-ST-439 in Dukes' C colorectal cancer patients: a preliminary report. Surg Today. 1999, 29 (1): 91-92. 10.1007/BF02482979.CrossRefPubMed Matsumoto K, Kinoshita T, Ishida T, Itoh H, Miki C, Suzuki H: Serum levels of NCC-ST-439 in Dukes' C colorectal cancer patients: a preliminary report. Surg Today. 1999, 29 (1): 91-92. 10.1007/BF02482979.CrossRefPubMed
26.
go back to reference McKeown DJ, Brown DJ, Kelly A, Wallace AM, McMillan DC: The relationship between circulating concentrations of C-reactive protein, inflammatory cytokines and cytokine receptors in patients with non-small-cell lung cancer. Br J Cancer. 2004, 91 (12): 1993-1995. 10.1038/sj.bjc.6602248.CrossRefPubMedPubMedCentral McKeown DJ, Brown DJ, Kelly A, Wallace AM, McMillan DC: The relationship between circulating concentrations of C-reactive protein, inflammatory cytokines and cytokine receptors in patients with non-small-cell lung cancer. Br J Cancer. 2004, 91 (12): 1993-1995. 10.1038/sj.bjc.6602248.CrossRefPubMedPubMedCentral
27.
go back to reference Borsellino N, Belldegrun A, Bonavida B: Endogenous interleukin 6 is a resistance factor for cis-diamminedichloroplatinum and etoposide-mediated cytotoxicity of human prostate carcinoma cell lines. Cancer Res. 1995, 55 (20): 4633-4639.PubMed Borsellino N, Belldegrun A, Bonavida B: Endogenous interleukin 6 is a resistance factor for cis-diamminedichloroplatinum and etoposide-mediated cytotoxicity of human prostate carcinoma cell lines. Cancer Res. 1995, 55 (20): 4633-4639.PubMed
28.
go back to reference Miki S, Iwano M, Miki Y, Yamamoto M, Tang B, Yokokawa K, Sonoda T, Hirano T, Kishimoto T: Interleukin-6 (IL-6) functions as an in vitro autocrine growth factor in renal cell carcinomas. FEBS Lett. 1989, 250 (2): 607-610. 10.1016/0014-5793(89)80805-1.CrossRefPubMed Miki S, Iwano M, Miki Y, Yamamoto M, Tang B, Yokokawa K, Sonoda T, Hirano T, Kishimoto T: Interleukin-6 (IL-6) functions as an in vitro autocrine growth factor in renal cell carcinomas. FEBS Lett. 1989, 250 (2): 607-610. 10.1016/0014-5793(89)80805-1.CrossRefPubMed
29.
go back to reference Takenawa J, Kaneko Y, Fukumoto M, Fukatsu A, Hirano T, Fukuyama H, Nakayama H, Fujita J, Yoshida O: Enhanced expression of interleukin-6 in primary human renal cell carcinomas. J Natl Cancer Inst. 1991, 83 (22): 1668-1672. 10.1093/jnci/83.22.1668.CrossRefPubMed Takenawa J, Kaneko Y, Fukumoto M, Fukatsu A, Hirano T, Fukuyama H, Nakayama H, Fujita J, Yoshida O: Enhanced expression of interleukin-6 in primary human renal cell carcinomas. J Natl Cancer Inst. 1991, 83 (22): 1668-1672. 10.1093/jnci/83.22.1668.CrossRefPubMed
30.
go back to reference Okamoto M, Hattori K, Oyasu R: Interleukin-6 functions as an autocrine growth factor in human bladder carcinoma cell lines in vitro. Int J Cancer. 1997, 72 (1): 149-154. 10.1002/(SICI)1097-0215(19970703)72:1<149::AID-IJC21>3.0.CO;2-D.CrossRefPubMed Okamoto M, Hattori K, Oyasu R: Interleukin-6 functions as an autocrine growth factor in human bladder carcinoma cell lines in vitro. Int J Cancer. 1997, 72 (1): 149-154. 10.1002/(SICI)1097-0215(19970703)72:1<149::AID-IJC21>3.0.CO;2-D.CrossRefPubMed
Metadata
Title
Preoperative serum C- reactive protein: a prognostic marker in patients with upper urinary tract urothelial carcinoma
Authors
Barbara Stein
Andres Jan Schrader
Gerd Wegener
Christoph Seidel
Markus A Kuczyk
Sandra Steffens
Publication date
01-12-2013
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2013
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-13-101

Other articles of this Issue 1/2013

BMC Cancer 1/2013 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine